Cells for Cells announces that the U.S. Patent and Trademark Office (USPTO) has granted the patent covering the AUTOMATED FABRICATION OF LAYER-BY-LAYER TISSUE ENGINEERED COMPLEX TUBES (US20180304502).
The approval now legally protects this invention which details a new strategy to fabricate advanced tissue engineered conduits for diverse applications intended to treat major medical conditions that affect millions of people worldwide. Moreover, this new intellectual property milestone positions the company at the forefront of developing innovative technology to address the critical need for vascular grafts.
In particular, the novel approach comprises the use of a robot that can achieve precise geometrical, mechanical and biological personalization of tissue-like conduits thanks to the controlled and automated deposition at high resolution of biomaterials, nanofibers and cells in a unique and rapid one-step fabrication procedure. The personalized tubes manufactured through this patented technology possess a multilayer structure that resembles the anatomy of tissue conduits that are replaced in the treatment of a multitude of different pathologies. Examples of applications that can benefit from these novel tissue conduits include arteries and veins, urethra and intestinal tissues.
Typically, the production of Tissue Engineered Products requires multiple steps that go from scaffold fabrication to cell seeding, maturation in bioreactors, and, ultimately, packaging, making the manufacturing of such solutions a long and inefficient process, which is, moreover, expensive and difficult to standardize. These manufacturing issues have been pointed out in the last years as the main drawbacks that are keeping advanced tissue engineered medical solutions commercially unfeasible and away from the clinical reality.
Aware of the aforementioned challenges, Cells for Cells Tissue Engineering and Biomaterials Unit led by Juan Pablo Acevedo, has worked to bring these tubular grafts closer to patients via the newly patented manufacturing approach. This allows for scalable tissue conduits to be ready to implant in less than an hour with guaranteed standardization and quality. The approach, which has been highlighted in prominent peer-reviewed scientific journals (Akentjew et al., Nature Communications, 2019), solved for the first time technical and commercial issues of the field and makes possible the quick manufacturing of very-needed tissue conduits near the point of treatment.